FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080202332> ?p ?o ?g. }

• W2080202332 endingPage "f2310" @default.
• W2080202332 startingPage "f2310" @default.
• W2080202332 abstract "<b>Objective</b> To assess the effectiveness of two peritendinous autologous blood injections in addition to a standardised eccentric calf strengthening programme in improving pain and function in patients with mid-portion Achilles tendinopathy. <b>Design</b> Single centre, participant and single assessor blinded, parallel group, randomised, controlled trial. <b>Setting</b> Single sports medicine clinic in New Zealand. <b>Participants</b> 53 adults (mean age 49, 53% men) with symptoms of unilateral mid-portion Achilles tendinopathy for at least three months. Participants were excluded if they had a history of previous Achilles tendon rupture or surgery or had undergone previous adjuvant treatments such as injectable therapies, glyceryl trinitrate patches, or extracorporeal shockwave therapy. <b>Interventions</b> All participants underwent two unguided peritendinous injections one month apart with a standardised protocol. The treatment group had 3 mL of their own whole blood injected while the control group had no substance injected (needling only). Participants in both groups carried out a standardised and monitored 12 week eccentric calf training programme. Follow-up was at one, two, three and six months. <b>Main outcome measures</b> The primary outcome measure was the change in symptoms and function from baseline to six months with the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes were the participant’s perceived rehabilitation and their ability to return to sport. <b>Results</b> 26 participants were randomly assigned to the treatment group and 27 to the control group. In total, 50 (94%) completed the six month study, with 25 in each group. Clear and clinically worthwhile improvements in the VISA-A score were evident at six months in both the treatment (change in score 18.7, 95% confidence interval 12.3 to 25.1) and control (19.9, 13.6 to 26.2) groups. The overall effect of treatment was not significant (P=0.689) and the 95% confidence intervals at all points precluded clinically meaningful benefit or harm. There was no significant difference between groups in secondary outcomes or in the levels of compliance with the eccentric calf strengthening programme. No adverse events were reported. <b>Conclusion</b> The administration of two unguided peritendinous autologous blood injections one month apart, in addition to a standardised eccentric training programme, provides no additional benefit in the treatment of mid-portion Achilles tendinopathy. <b>Trial registration</b> Australian New Zealand Clinical Trials Registry ACTRN12610000824066, WHO U1111-1117-2641." @default.
• W2080202332 created "2016-06-24" @default.
• W2080202332 creator A5029402906 @default.
• W2080202332 creator A5031827995 @default.
• W2080202332 creator A5056605184 @default.
• W2080202332 creator A5062925543 @default.
• W2080202332 date "2013-04-18" @default.
• W2080202332 modified "2023-10-16" @default.
• W2080202332 title "Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial" @default.
• W2080202332 cites W105350838 @default.
• W2080202332 cites W1975197231 @default.
• W2080202332 cites W1977691008 @default.
• W2080202332 cites W1984002790 @default.
• W2080202332 cites W1994811861 @default.
• W2080202332 cites W1996259670 @default.
• W2080202332 cites W1999632031 @default.
• W2080202332 cites W2000243207 @default.
• W2080202332 cites W2003956201 @default.
• W2080202332 cites W2015479305 @default.
• W2080202332 cites W2020136844 @default.
• W2080202332 cites W2027592012 @default.
• W2080202332 cites W2049958856 @default.
• W2080202332 cites W2059470830 @default.
• W2080202332 cites W2066168728 @default.
• W2080202332 cites W2073536637 @default.
• W2080202332 cites W2078693455 @default.
• W2080202332 cites W2083109402 @default.
• W2080202332 cites W2094227270 @default.
• W2080202332 cites W2105317767 @default.
• W2080202332 cites W2106225896 @default.
• W2080202332 cites W2107026068 @default.
• W2080202332 cites W2115965890 @default.
• W2080202332 cites W2117562809 @default.
• W2080202332 cites W2119632244 @default.
• W2080202332 cites W2120411685 @default.
• W2080202332 cites W2129382396 @default.
• W2080202332 cites W2136871488 @default.
• W2080202332 cites W2137270584 @default.
• W2080202332 cites W2138005774 @default.
• W2080202332 cites W2141182405 @default.
• W2080202332 cites W2142354391 @default.
• W2080202332 cites W2143488080 @default.
• W2080202332 cites W2152308909 @default.
• W2080202332 cites W2156013958 @default.
• W2080202332 cites W2157416943 @default.
• W2080202332 cites W2158175963 @default.
• W2080202332 cites W2161615595 @default.
• W2080202332 cites W2163241040 @default.
• W2080202332 cites W2167318300 @default.
• W2080202332 cites W2168123920 @default.
• W2080202332 cites W2168857629 @default.
• W2080202332 cites W2169855243 @default.
• W2080202332 cites W2226230461 @default.
• W2080202332 doi "https://doi.org/10.1136/bmj.f2310" @default.
• W2080202332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3629924" @default.
• W2080202332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23599320" @default.
• W2080202332 hasPublicationYear "2013" @default.
• W2080202332 type Work @default.
• W2080202332 sameAs 2080202332 @default.
• W2080202332 citedByCount "67" @default.
• W2080202332 countsByYear W20802023322013 @default.
• W2080202332 countsByYear W20802023322014 @default.
• W2080202332 countsByYear W20802023322015 @default.
• W2080202332 countsByYear W20802023322016 @default.
• W2080202332 countsByYear W20802023322017 @default.
• W2080202332 countsByYear W20802023322018 @default.
• W2080202332 countsByYear W20802023322019 @default.
• W2080202332 countsByYear W20802023322020 @default.
• W2080202332 countsByYear W20802023322021 @default.
• W2080202332 countsByYear W20802023322022 @default.
• W2080202332 countsByYear W20802023322023 @default.
• W2080202332 crossrefType "journal-article" @default.
• W2080202332 hasAuthorship W2080202332A5029402906 @default.
• W2080202332 hasAuthorship W2080202332A5031827995 @default.
• W2080202332 hasAuthorship W2080202332A5056605184 @default.
• W2080202332 hasAuthorship W2080202332A5062925543 @default.
• W2080202332 hasBestOaLocation W20802023321 @default.
• W2080202332 hasConcept C100784341 @default.
• W2080202332 hasConcept C108305453 @default.
• W2080202332 hasConcept C118552586 @default.
• W2080202332 hasConcept C121332964 @default.
• W2080202332 hasConcept C126322002 @default.
• W2080202332 hasConcept C141071460 @default.
• W2080202332 hasConcept C142724271 @default.
• W2080202332 hasConcept C168563851 @default.
• W2080202332 hasConcept C1862650 @default.
• W2080202332 hasConcept C204243189 @default.
• W2080202332 hasConcept C204787440 @default.
• W2080202332 hasConcept C27415008 @default.
• W2080202332 hasConcept C2777785397 @default.
• W2080202332 hasConcept C2778104025 @default.
• W2080202332 hasConcept C2778818304 @default.
• W2080202332 hasConcept C2778911562 @default.
• W2080202332 hasConcept C2779751750 @default.
• W2080202332 hasConcept C2780105995 @default.
• W2080202332 hasConcept C2780984734 @default.
• W2080202332 hasConcept C56837625 @default.
• W2080202332 hasConcept C62520636 @default.

• next